CHPA NDAC nomination
This article was originally published in The Tan Sheet
Executive Summary
CHPA nominates George Goldstein, MD, to represent the industry on FDA's Nonprescription Drugs Advisory Committee, the organization states in a Nov. 28 letter to FDA. The Consumer Healthcare Products Association polled members to identify Goldstein as the "consensus candidate" for industry representative. Goldstein comes to the table with a resume that includes 14 years in private practice as a pediatrician and 15 years with Sterling Drug, according to CHPA. Goldstein served as Chief Medical Officer for Sterling's OTC division, Glenbrook Labs, as well as for the Rx division, Winthrop Labs. FDA announced in November that it was taking nominations for a non-voting industry representative to serve on the committee ("The Tan Sheet" Nov. 21, 2005, In Brief)...
You may also be interested in...
NDAC nominations
Nominations for a non-voting industry representative to serve on the Nonprescription Drugs Advisory Committee must be received by FDA no later than Dec. 15, the agency announces in the Nov. 15 Federal Register. Industry organizations interested in participating in the member's selection should notify FDA by letter. The agency will compile a list of nominees by Dec. 15 and will forward the list to participating organizations. A candidate must be selected by participants within 60 days of receipt of the FDA letter. If no candidate is chosen, the FDA commissioner will select the non-voting member, FDA notes. Self-nominations are acceptable and organizations may submit multiple nominations...
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: